Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia

被引：17

作者：

Suzushima, Hitoshi ^{[1
]}

Wada, Naoko ^{[2
]}

Yamasaki, Hiroshi ^{[3
]}

Eto, Kenichiro ^{[4
]}

Shimomura, Taizo ^{[1
]}

Kugimiya, Michiko H. ^{[1
]}

Horikawa, Kentaro ^{[2
]}

Nishimura, Shintaro ^{[4
]}

Tsuda, Hiroyuki ^{[3
]}

Mitsuya, Hiroaki ^{[2
]}

Asou, Norio ^{[2
]}

机构：

[1] NTT W Kyushu Hosp, Dept Hematol & Immunol, Kumamoto 8628655, Japan

[2] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 860, Japan

[3] Kumamoto City Hosp, Dept Hematol & Oncol, Kumamoto, Japan

[4] Yatsushiro Gen Hosp, Dept Hematol, Yatsushiro, Japan

来源：

LEUKEMIA RESEARCH | 2010年 / 34卷 / 05期

关键词：

Elderly acute myeloid leukemia; Low-dose chemotherapy; Cytarabine; Aclarubicin; Granulocyte colony-stimulating factor; CAG; ACUTE MYELOGENOUS LEUKEMIA; RISK MYELODYSPLASTIC SYNDROME; OLDER-ADULTS; ARA-C; INDUCTION CHEMOTHERAPY; PROGNOSTIC-FACTORS; COMPLETE REMISSION; COOPERATIVE-GROUP; ONCOLOGY-GROUP; CAG REGIMEN;

D O I：

10.1016/j.leukres.2009.08.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We evaluated the efficacy of low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor (CAG) in elderly patients with previously untreated acute myeloid leukemia. Patients aged between 60 and 70 years who were not eligible for standard chemotherapy protocols and patients aged over 70 years were all registered. Thirty-three of 68 patients (49%) achieved remission. Median disease-free survival was 10 months and overall survival was nine months. Performance status after chemotherapy in patients who achieved remission was generally favorable. The present study demonstrates that CAG therapy is efficacious and well tolerated in the majority of elderly patients. (C) 2009 Elsevier Ltd. All rights reserved.

引用

页码：610 / 614

页数：5

共 50 条

[21] Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report
Deng, Qi
Li, Jing-Yi
Liu, Peng-Jiang
Zhao, Ming-Feng
[J]. ONCOLOGY LETTERS, 2015, 9 (03) : 1217 - 1220
[22] Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients
Xue, Sheng-Li
Cui, Hong-Xia
Zou, Jing-Ying
Xue, Meng-Xing
Tang, Xiao-Wen
Zhang, Yan-Ming
Wu, De-Pei
[J]. HEMATOLOGICAL ONCOLOGY, 2013, 31 (04) : 206 - 212
[23] Priming with granulocyte colony-stimulating factor - Relation to high-dose cytarabine in acute myeloid leukemia
Buchner, T
Berdel, WE
Hiddemann, W
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21): : 2215 - 2216
[24] Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia
Liu-Fang Gu
Wang-Gang Zhang
Fang-Xia Wang
Xing-Mei Cao
Yin-Xia Chen
Ai-Li He
Jie Liu
Xiao-Rong Ma
[J]. Journal of Cancer Research and Clinical Oncology, 2011, 137 : 997 - 1003
[25] Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china
Liu, Haihui
Zhang, Jingjing
Ren, Saisai
Chen, Mingtai
Liu, Lulu
Zhang, Hao
[J]. LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2758 - 2761
[26] Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia
Gu, Liu-Fang
Zhang, Wang-Gang
Wang, Fang-Xia
Cao, Xing-Mei
Chen, Yin-Xia
He, Ai-Li
Liu, Jie
Ma, Xiao-Rong
[J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (06) : 997 - 1003
[27] Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model
Chen, Jinqiu
Yang, Nan
Liu, Hailing
Yao, Huan
Wang, Jin
Yang, Yun
Zhang, Wanggang
[J]. ONCOLOGY LETTERS, 2018, 16 (03) : 3022 - 3028
[28] Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: A multicenter study of 112 Chinese patients
Li, JM
Shen, Y
Wu, DR
Liang, H
Jin, J
Chen, EY
Song, YP
Wang, JM
Qiu, XF
Hou, M
Qiu, ZC
Shen, ZX
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 82 (01) : 48 - 54
[29] Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia
Ohno, R
[J]. LEUKEMIA RESEARCH, 1998, 22 (12) : 1143 - 1154
[30] Aclarubicin and Low-Dose Cytosine Arabinoside in Combination with Granulocyte Colony-Stimulating Factor in Treating Acute Myeloid Leukemia Patients with Relapsed or Refractory Disease and Myelodysplastic Syndrome: A Multicenter Study of 112 Chinese Patients
J. M. Li
Y. Shen
D. P. Wu
H. Liang
J. Jin
F. Y. Chen
Y. P. Song
J. M. Wang
X. F. Qiu
M. Hou
Z. C. Qiu
Z. X. Shen
[J]. International Journal of Hematology, 2005, 82 : 48 - 54

← 1 2 3 4 5 →